Esophageal Cancer Drugs Market
According to Intent Market Research, the Esophageal Cancer Drugs Market is expected to grow from USD 3.8 billion in 2023 at a CAGR of 7.1% to touch USD 6.1 billion by 2030. The Esophageal Cancer Drugs Market is dominated by key players such as Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca PLC, Roche Holding AG, Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, Amgen Inc., AbbVie Inc., Boehringer Ingelheim, Sanofi S.A., Gilead Sciences, Takeda Pharmaceutical Company Limited, Bayer AG